咽頭癌治療法の世界市場予測・分析2019-2023

◆英語タイトル:Pharyngeal Cancer Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
◆商品コード:IRTNTR32066
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年9月28日
◆ページ数:153
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥280,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、咽頭癌治療法の世界市場について調べ、咽頭癌治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、咽頭癌治療法の市場規模をセグメンテーション別(製品別(標的療法、化学療法)、)と地域別(グローバル)に分けて算出しました。Technavio社は咽頭癌治療法の世界市場規模が2019-2023期間中に年平均6%成長すると予測しています。
・サマリー
・レポートの範囲
・咽頭癌治療法の市場状況
・咽頭癌治療法の市場規模
・咽頭癌治療法の市場予測
・咽頭癌治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(標的療法、化学療法)
・咽頭癌治療法の顧客状況
・主要地域別市場規模:グローバル
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Pharyngeal Cancer Market: About this market

Technavio’s pharyngeal cancer market analysis considers sales from targeted therapy and chemotherapy products. Our analysis also considers the sales of pharyngeal cancer in Asia, Europe, North America, and ROW. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the development of novel targeted therapies will play a significant role in the targeted therapy segment to maintain its market position. Also, our global pharyngeal cancer market report looks at factors such as high-risk factors for pharyngeal cancer, increasing geriatric population, and increasing awareness of pharyngeal cancer. However, availability of alternative treatment options, adverse effects of chemotherapy, and high cost of targeted therapy may hamper the growth of the pharyngeal cancer industry over the forecast period.

Global Pharyngeal Cancer Market: Overview

High-risk factors for pharyngeal cancer

Pharyngeal cancer is one of the most common types of cancer as it largely attributed to the prevalence of high-risk factors such as increase in the use of tobacco, excessive alcohol consumption, increase in viral infections, and occupational exposure. Viral infections associated with the throat can lead to the development of throat cancer, including pharyngeal cancer. Moreover, individuals working in high-dose radiation environments can also develop pharyngeal cancer as they are exposed to certain chemicals, dust, or fumes. Thus, such high-risk factors for pharyngeal cancer will lead to the expansion of the global pharyngeal cancer market at a CAGR of over 6% during the forecast period.

Emergence of pipeline molecules

Despite the high prevalence of pharyngeal cancer, there is a lack of approved targeted therapy drugs for treatment. This is encouraging vendors to invest significantly in the development of novel therapeutics with limited side effects. For instance, Roche is developing TECENTRIQ, which is a novel PD-L1 monoclonal antibody to prevent cancer immune evasion. The filing of this molecule is expected in 2022, and it is expected to receive marketing approval by the end of the forecast period. Similarly, AstraZeneca is also conducting clinical trials of durvalumab, a PD-L1 molecule in combination with different drugs.  Thus, the expected approvals of the late-stage pipeline molecules are anticipated to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global pharyngeal cancer market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global pharyngeal cancer market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading pharyngeal cancer manufacturers, that include AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Also, the pharyngeal cancer market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Targeted therapy – Market size and forecast 2018-2023

Chemotherapy – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Emergence of pipeline molecules

Presence of reimbursement and patient assistance programs

Advent of novel therapies

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

AstraZeneca Plc

Bristol-Myers Squibb Co.

Eli Lilly and Co.

F. Hoffmann-La Roche Ltd.

Merck & Co. Inc.

Mylan NV

Pfizer Inc.

Sanofi

Sun Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Product overview

Exhibit 02: Global pharmaceuticals market

Exhibit 03: Segments of global pharmaceuticals market

Exhibit 04: Market characteristics

Exhibit 05: Market segments

Exhibit 06: Market definition – Inclusions and exclusions checklist

Exhibit 07: Market size 2018

Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Product – Market share 2018-2023 (%)

Exhibit 19: Comparison by product

Exhibit 20: Targeted therapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 21: Targeted therapy – Year-over-year growth 2019-2023 (%)

Exhibit 22: Chemotherapy – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Chemotherapy – Year-over-year growth 2019-2023 (%)

Exhibit 24: Market opportunity by product

Exhibit 25: Customer landscape

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Top 3 countries in North America

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Top 3 countries in Europe

Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 36: Top 3 countries in Asia

Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in ROW

Exhibit 40: Key leading countries

Exhibit 41: Market opportunity

Exhibit 42: Adverse effects of common chemotherapy drugs

Exhibit 43: Impact of drivers and challenges

Exhibit 44: Vendor landscape

Exhibit 45: Landscape disruption

Exhibit 46: Vendors covered

Exhibit 47: Vendor classification

Exhibit 48: Market positioning of vendors

Exhibit 49: AstraZeneca Plc – Vendor overview

Exhibit 50: AstraZeneca Plc – Business segments

Exhibit 51: AstraZeneca Plc – Organizational developments

Exhibit 52: AstraZeneca Plc – Geographic focus

Exhibit 53: AstraZeneca Plc – Key offerings

Exhibit 54: AstraZeneca Plc – Key customers

Exhibit 55: Bristol-Myers Squibb Co. – Vendor overview

Exhibit 56: Bristol-Myers Squibb Co. – Business segments

Exhibit 57: Bristol-Myers Squibb Co. – Organizational developments

Exhibit 58: Bristol-Myers Squibb Co. – Geographic focus

Exhibit 59: Bristol-Myers Squibb Co. – Key offerings

Exhibit 60: Bristol-Myers Squibb Co. – Key customers

Exhibit 61: Eli Lilly and Co. – Vendor overview

Exhibit 62: Eli Lilly and Co. – Business segments

Exhibit 63: Eli Lilly and Co. – Organizational developments

Exhibit 64: Eli Lilly and Co. – Geographic focus

Exhibit 65: Eli Lilly and Co. – Segment focus

Exhibit 66: Eli Lilly and Co. – Key offerings

Exhibit 67: Eli Lilly and Co. – Key customers

Exhibit 68: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 69: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 70: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 71: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 72: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 73: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 74: F. Hoffmann-La Roche Ltd. – Key customers

Exhibit 75: Merck & Co. Inc. – Vendor overview

Exhibit 76: Merck & Co. Inc. – Business segments

Exhibit 77: Merck & Co. Inc. – Organizational developments

Exhibit 78: Merck & Co. Inc. – Geographic focus

Exhibit 79: Merck & Co. Inc. – Segment focus

Exhibit 80: Merck & Co. Inc. – Key offerings

Exhibit 81: Merck & Co. Inc. – Key customers

Exhibit 82: Mylan NV – Vendor overview

Exhibit 83: Mylan NV – Product segments

Exhibit 84: Mylan NV – Organizational developments

Exhibit 85: Mylan NV – Geographic focus

Exhibit 86: Mylan NV – Segment focus

Exhibit 87: Mylan NV – Key offerings

Exhibit 88: Mylan NV – Key customers

Exhibit 89: Pfizer Inc. – Vendor overview

Exhibit 90: Pfizer Inc. – Business segments

Exhibit 91: Pfizer Inc. – Organizational developments

Exhibit 92: Pfizer Inc. – Geographic focus

Exhibit 93: Pfizer Inc. – Segment focus

Exhibit 94: Pfizer Inc. – Key offerings

Exhibit 95: Pfizer Inc. – Key customers

Exhibit 96: Sanofi – Vendor overview

Exhibit 97: Sanofi – Business segments

Exhibit 98: Sanofi – Organizational developments

Exhibit 99: Sanofi – Geographic focus

Exhibit 100: Sanofi – Segment focus

Exhibit 101: Sanofi – Key offerings

Exhibit 102: Sanofi – Key customers

Exhibit 103: Sun Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 104: Sun Pharmaceutical Industries Ltd. – Business segments

Exhibit 105: Sun Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 106: Sun Pharmaceutical Industries Ltd. – Geographic focus

Exhibit 107: Sun Pharmaceutical Industries Ltd. – Key offerings

Exhibit 108: Sun Pharmaceutical Industries Ltd. – Key customers

Exhibit 109: Teva Pharmaceutical Industries Ltd. – Vendor overview

Exhibit 110: Teva Pharmaceutical Industries Ltd. – Business segments

Exhibit 111: Teva Pharmaceutical Industries Ltd. – Organizational developments

Exhibit 112: Teva Pharmaceutical Industries Ltd. – Segment focus

Exhibit 113: Teva Pharmaceutical Industries Ltd. – Key offerings

Exhibit 114: Teva Pharmaceutical Industries Ltd. – Key customers

Exhibit 115: Validation techniques employed for market sizing

Exhibit 116: Definition of market positioning of vendors



【掲載企業】

AstraZeneca Plc, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[咽頭癌治療法の世界市場予測・分析2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆